It is possible that JC's tenure period was either agreed upon...

It is possible that JC's tenure period was either agreed upon from the outset or naturally took the course it did under the milestones achieved to this juncture. Three novel therapy platforms with several synergised combo-therapies in the clinic Congratulations on a job well done, thank you for your service, and make sure to promote our assets wherever you go, Jenn.

With the stake she inherited in the company why wouldn't she promote CHM's platforms? As a former CEO, she may even have more credibility in any promotions she initiates on our behalf. Who knows what collaborations JC's future endeavors may bring for our assets? Depending on the caliber and expertise of the new CEO, this could be a very fortunate moment in CHM's development. Two therapies nearing Ph2 trials with the potential to become registration trials. In hindsight, yesterday's news could be a positive.

Anyone devoting their life to the field of immunotherapy and commanding a salary to the tune of half a million a year post-tax is most likely to have a philanthropic agenda when it comes to the shares inherited in the companies they have worked for. That could also mean shifting money from one investment to another, of course. However, I'm sure she will give her investment time to appreciate in light of how undervalued CHM potentially is. Interesting times ahead for CHM, that's for sure.